# US 2026/0060957 A1 · Compounds and compositions useful for treatment of proliferative disease or disorder

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0060957 A1
- Document ID: US20260060957A1
- Status: Published application
- Kind: A1
- Application number: 19/308,852
- Filed: 2025-08-25
- Published: 2026-03-05
- Earliest claimed: 2023-10-24
- Assignees: University of Houston System; Tract Pharmaceuticals, Inc.
- Applicants: University of Houston System; Tract Pharmaceuticals, Inc.
- Inventors: Wa Xian; Frank McKeon; Matthew Vincent; Richard E. Russell
- Web page: https://patentgrep.com/patent/US20260060957A1

## CPC

- A61K 31/4025: not condensed and containing further heterocyclic rings, e.g. cromakalim
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 31/4192: 1,2,3-Triazoles
- A61K 31/495: having six-membered rings with two {or more} nitrogen atoms as the only ring heteroatoms, e.g. piperazine {or tetrazines}(A61K31/48 takes precedence {; with three nitrogen atoms A61K31/53})
- A61K 31/5025: ortho- or peri-condensed with heterocyclic ring systems
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/545: {Heterocyclic compounds (A61K47/558 takes precedence)}
- A61K 47/55: the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
- A61K 47/555: {pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells}
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure provides compounds, pharmaceutically acceptable compositions thereof and methods of using the same.

## Claims

### Claim 1

A pharmaceutical composition comprising an IAP inhibitor and a cellular kinase inhibitor wherein the IAP inhibitor is a compound of formula I:
or a pharmaceutically acceptable salt thereof,
wherein:
L1 is a first ligand;
L2 is a second ligand; and
linker is a bivalent linker comprising

### Claim 2 (depends on 1)

The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is a single entity.

### Claim 3 (depends on 2)

The pharmaceutical composition of claim 2, wherein the pharmaceutical composition is a unit dosage form.

### Claim 4

A combination comprising:
an IAP inhibitor; and
a cellular kinase inhibitor
wherein the IAP inhibitor is a compound of formula I:
or a pharmaceutically acceptable salt thereof,
wherein:
L1 is a first ligand;
L2 is a second ligand; and
linker is a bivalent linker comprising

### Claim 5

(canceled)

### Claim 6

A method of treating a proliferative disorder comprising administering to a subject in need thereof combination therapy with an IAP inhibitor and a cellular kinase inhibitor
wherein the IAP inhibitor is a compound of formula I:
or a pharmaceutically acceptable salt thereof,
wherein:
L1 is a first ligand;
L2 is a second ligand; and
linker is a bivalent linker comprising

### Claim 7 (depends on 6)

The method of claim 6 comprising administering the IAP inhibitor to the subject in need thereof wherein the subject has received or is receiving the cellular kinase inhibitor.

### Claim 8 (depends on 6)

The method of claim 6 comprising administering the cellular kinase inhibitor to he subject in need thereof wherein the subject has received or is receiving the IAP inhibitor.

### Claim 9

(canceled)

### Claim 10 (depends on 6)

The method of claim 6 wherein the proliferative disorder is a pulmonary disease or disorder.

### Claim 11 (depends on 6)

The method of claim 6 wherein the proliferative disorder is a cancer.

### Claim 12 (depends on 6)

The method of claim 6 wherein the cellular kinase inhibitor and the IAP inhibitor are delivered in the same composition.

### Claim 13 (depends on 6)

The method of claim 6 wherein the cellular kinase inhibitor and the IAP inhibitor are not delivered in the same composition.

### Claim 14 (depends on 6)

The method of claim 6 wherein the cellular kinase inhibitor is a tyrosine kinase inhibitor.

### Claim 15 (depends on 14)

The method of claim 14 wherein the cellular kinase inhibitor is ponatinib.

### Claim 16

(canceled)

### Claim 17 (depends on 6)

The method of claim 6, wherein each of L1 and L2 is independently a moiety that binds to one or more Inhibitor of Apoptosis Proteins (IAPs).

### Claim 18

(canceled)

### Claim 19 (depends on 17)

The composition or method of claim 17, wherein each of L1 and L2 independently comprises a group selected from:
or a pharmaceutically acceptable salt thereof.

### Claim at position 20

-23. (canceled)

### Claim 24 (depends on 17)

The composition or method of claim 17, wherein the compound is of formula I-a, I-b, or I-c:
or a pharmaceutically acceptable salt thereof.

### Claim 25 (depends on 6)

The method of claim 6, wherein the linker is of formula X:
or a pharmaceutically acceptable salt thereof, wherein:
each of X1 and X2 is independently a covalent bond or an optionally substituted bivalent, saturated or partially unsaturated, straight or branched C1-12 hydrocarbon chain, wherein 1-4 carbon atoms are optionally and independently replaced by —O—, —N(R)—, —C(O)—, —S—, —SO—, —SO2—, or -Cy-;
each R is independently selected from hydrogen or an optionally substituted C1-6 aliphatic;
each -Cy- is independently an optionally substituted bivalent ring selected from a 3- to 8-membered carbocyclene, a 5- to 6-membered saturated or partially unsaturated heterocyclene having 1-3 heteroatoms independently selected from oxygen, nitrogen, or sulfur; phenylene; or a 5- to 6-membered heteroarylene having 1-3 heteroatoms independently selected from oxygen, nitrogen, or sulfur;
#represents the point of attachment to L1; and
$ represents the point of attachment to L2.

### Claim 26 (depends on 25)

The method of claim 25, wherein X1 and X2 are the same.

### Claim 27 (depends on 25)

The method of claim 25, wherein X1 and X2 are different.

### Claim at position 25

-36. (canceled)

### Claim 37 (depends on 6)

The method of claim 6, wherein X1 is:
covalent bond,
wherein #represents the point of attachment to L1.

### Claim at position 27

-45. (canceled)

### Claim 46 (depends on 6)

The method of claim 6, wherein X2 is:
covalent bond,
wherein $ represents the point of attachment to L2.

### Claim at position 29

-50. (canceled)

### Claim 51 (depends on 19)

The composition or method of claim 19, wherein the compound is selected from:
or a pharmaceutically acceptable salt thereof.

### Claim 52 (depends on 11)

The method of claim 11, wherein the cancer is bladder cancer, breast cancer, colon cancer, liver cancer, lung cancer, ovarian cancer, esophageal cancer, cholangiocarcinoma, glioblastoma, medulloblastoma, pancreatic cancer, or prostate cancer.

### Claim 53 (depends on 10)

The method of claim 10, wherein the pulmonary disease or disorder is chronic obstructive pulmonary disease (COPD), cystic fibrosis, idiopathic pulmonary fibrosis or COVID-19.

### Claim 54

A pharmaceutical composition comprising an IAP inhibitor for use in combination with a cellular kinase inhibitor
wherein the IAP inhibitor is a compound of formula I:
or a pharmaceutically acceptable salt thereof,
wherein:
L1 is a first ligand;
L2 is a second ligand; and
linker is a bivalent linker comprising
